A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

NCT05766410 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Hormone Receptor-positive Breast Cancer
Hormone Therapy

Interventions

DRUG: Palbociclib
DRUG: Ribociclib
DRUG: Abemaciclib
DRUG: Letrozole

Sponsor

National Taiwan University Hospital